# A Study of MabThera (Rituximab) Plus Chlorambucil in Participants With Chronic Lymphocytic Leukemia.

> **NCT00532129** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 100 (actual)

## Conditions studied

- Lymphocytic Leukemia, Chronic

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Chlorambucil

## Key facts

- **NCT ID:** NCT00532129
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2016-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00532129

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00532129, "A Study of MabThera (Rituximab) Plus Chlorambucil in Participants With Chronic Lymphocytic Leukemia.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00532129. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*